The Rb tumor suppressor gene is mutated in approximately 25 percent of breast cancers, and a larger percentage show alterations in the pRb pathway resulting from overexpression of cyclin D1 or loss of p16 [14], [15]. This evidence concerns the gene CDKN2A and breast cancer.